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Abstract
Objective. To examine the characteristics and frequency of disease flares in a cohort of people with AS.
Methods. A prospective data set from a randomized controlled trial (RCT) of a probiotic treatment/
placebo was utilized to examine disease flares in 134 people with AS. Disease flares were defined as
either minor/localized flares (pain/swelling localized to one area with fatigue and stiffness) or major/
generalized flares (generalized pain, hot burning joints, muscle spasm, fever, sweating, extreme fatigue
and stiffness).
Results. One hundred and thirty-four people were followed up for 1216 person follow-up weeks and there
were 71.4 flares per 100 person-weeks. Of these, 12 were major/generalized flares and 59.4 were minor/
localized flares. People who experienced at least one major/generalized flare during the study period had
worse disease during flare-free periods in terms of disease activity, impaired function, self-reported night
pain and iritis compared with those who did not experience any major/generalized flares during the study.
Major/generalized flares lasted for an average of 2.4 weeks (S.D. 2.7), and were preceded by and followed
by a minor/localized flare in 92% (55/60) of cases.
Conclusion. Seventy per cent of people with AS felt they had a flare in any given week. Those who
experienced major/generalized flares appear to have more severe and active disease even during periods
when not in flare, compared with those who do not experience major/generalized flares. These results
have implications for the timing of assessments prior to starting anti-TNF therapy and suggest that the
presence of major flares may be helpful in identifying patients with severe disease.
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Introduction
AS is a chronic inflammatory rheumatic disease that pri-
marily affects the spine and SI joints but may also affect
the peripheral joints, eyes, skin and bowel. The natural
history of AS remains poorly documented and the disease
course varies significantly between patients and over time
within the same patient. Like other chronic inflammatory
rheumatic diseases, AS appears to be characterized by
bouts of partial remission and exacerbations of disease
activity or flares [1].
In the UK, the NICE (National Institute for Health and
Clinical Excellence) guidelines for use of anti-TNF therapy
in AS require two assessments of disease activity at least
12 weeks apart to avoid unnecessary treatment of flares
of disease activity that may remit spontaneously [2]. There
are just two previous studies examining disease flares in
AS and these suggest that the majority of patients with AS
will experience flares [3, 4]. However, an agreed objective
definition of flare does not yet exist.
Using a flare illustration tool, Stone et al. [4] found that
the majority of patients retrospectively reported flares
superimposed on background disease activity. Although
all the patients reported flares in disease activity, there
appeared to be two patterns of AS flares: localized
(or minor) and generalized (or major) [3]. Localized flares
were described as pain and immobility in one area, with
relatively minor systemic symptoms (fatigue or stiffness),
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with patients reporting severe pain and immobility, in
addition to marked systemic features (sweats, fevers,
flu-like symptoms, marked fatigue and emotion symptoms
such as depression, withdrawal and anger). Patients
reported that both localized and generalized flares could
last from days to weeks [3, 4]. This study set out to exam-
ine prospectively the self-reported pattern of these
disease flares and their effects in patients with AS.
Patients and methods
Recruitment
Participants were recruited as part of an Internet-based
randomized controlled trial (RCT) of probiotics in AS [5].
This study had ethical approval from the London Multi-
centre Research Ethics Committee. Briefly, adult patients
with AS living in the UK were recruited via a link on the
National Ankylosing Spondylitis Society (NASS) website.
Participants printed out consent forms from the website,
which they signed and returned to the researchers. In
providing consent, participants also agreed to have their
doctor contacted to confirm that they had AS. The
rheumatologist or general medical doctor was asked
to confirm, using the patient’s notes, that the patient
had radiologically proven involvement of the SI joints.
Therefore, all patients included in the study had confirmed
AS and none of the participants had only peripheral
arthropathy. In addition, the doctors were asked to con-
firm the presence of other associated conditions (such as
iritis, psoriasis or IBD). The RCT found that the interven-
tion (probiotic) did not have a significant effect on the
disease scores of participants [5]. Therefore, the data
from both the placebo and intervention arm are reported
here. The baseline assessment included demographic
and disease data. On the same day each week for
3 months, participants completed an online questionnaire
related to their disease.
Outcome measure
Every week participants were asked if they had had
a disease flare in the past 7 days and, if so, whether this
was a localized/minor flare (the exact wording used was
‘pain/swelling localized one area with fatigue and stiff-
ness’) or generalized/major flare (‘generalized pain, hot
burning joints, muscle spasm, fever, sweating, extreme
fatigue and stiffness’). At the same time, patients com-
pleted questionnaires on disease activity [Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI)] [6], function
[Bath Ankylosing Spondylitis Functional Index (BASFI)] [7],
night pain (0–10 visual analogue scale with the question:
‘How would you describe the overall level of night pain
you have?’) and iritis.
Statistical analysis
STATA was used for all analysis. The STATA st command
was used to perform all time to event (survival) analysis.
Matched-pair t-tests were used on all within-patient
(intra-patient) comparisons.
Results
Characteristics ofcohort
Baseline characteristics of 134 AS participants (93 males
and 41 females) showed a mean age of 44 (S.D. 13; min–
max 20–81) years and mean disease duration from the
time of first symptom of 21 (S.D. 13; min–max 0–58)
years. Baseline disease activity (BASDAI) and function
(BASFI) were 3.7 (S.D. 2.1) and 3.6 (S.D. 2.8), respectively.
Prevalence ofdisease flares
One hundred and thirty-four people were followed up for
1216 person follow-up weeks and 869 (146 major and 723
minor) weeks of flare were reported. This prevalence gives
an overall flare rate of 71.4 per 100 person-weeks (95% CI
66.8, 76.3), a major flare rate of 12.0 per 100 person-
weeks (95% CI 10.2, 14.1) and 59.4 minor flares per 100
person-weeks (95% CI 55.2, 63.9).
Intra-patient comparison—localized or minor flares
There were 77 participants who reported at least one
period of localized/minor flare and one flare-free period.
The BASDAI, BASFI and night pain scores were signifi-
cantly higher during the period of minor flare compared
with the scores during the no flare period (Table 1). The
increase in the disease activity score during a minor flare
reached a clinically relevant difference [8] (>1.0cm
on BASDAI 0–10cm scale). However, the deterioration in
function during a minor flare did not reach a clinically rel-
evant difference (>0.7cm on the BASFI 0–10-cm
scale) [8].
TABLE 1 Change in measures of disease according to
flare
Intra-patient
comparison—minor/
localized flare
Minor
flare
(n=77)
Flare
free
(n=77)
Difference
(95% CI)
BASDAI, mean (S.D.) 3.1 (1.8) 1.8 (1.5) 1.26 (0.95, 1.6)
BASFI, mean (S.D.) 3.1 (2.6) 2.5 (2.7) 0.56 (0.34, 0.78)
Night pain, mean (S.D.) 2.8 (2.0) 1.5 (1.8) 1.3 (0.92, 1.68)
Iritis, n (%) 9 (12) 0 (0)
Intra-patient
comparison—major/
generalized flare
Major
flare
(n=27)
Flare
free
(n=27)
Difference
(95% CI)
BASDAI, mean (S.D.) 5.5 (2.1) 2.5 (1.7) 3.0 (2.3, 3.7)
BASFI, mean (S.D.) 5.5 (2.9) 3.5 (3.0) 2 (1.2, 2.7)
Night pain, mean (S.D.) 5.7 (3.2) 2.4 (1.9) 3.3 (2.3, 4.4)
Iritis, n (%) 3 (11) 0 (0)
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There were 27 participants who reported at least one
period of generalized/major flare and also one period of
no flare. During the major flare period there was a statis-
tically significant and clinically relevant increase in disease
activity, night pain and function. In addition, there were
more episodes of iritis during a period of flare (Table 1).
Characteristics ofparticipants experiencing
amajor/generalized flare
Participants who reported a period of major/generalized
flare during the study had higher disease activity, night
pain and poorer functional scores when they were
not experiencing a flare (flare-free period) compared
with participants who did not experience any major/
generalized flares (Table 2). Therefore, the non-flare level
of disease in the ‘major flare’ participants was higher than
in the ‘non-major flare’ participants.
The participants who reported a major flare did not
differ significantly in terms of gender, age, age at onset
or disease duration compared with participants who did
not report a major flare during this period (63% males:
46, 24 and 21 years; and 74% males: 43, 23 and 19 years).
Major/generalized flares appear to build up gradually
with 92% (55/60) of major/generalized flares being
preceded by a minor/localized flare. Similarly, 92% of
participants (55/60) reported a minor/localized flare after
the major flare.
Major/generalized flares were reported to last for an
average of 2.4 weeks (S.D. 2.7, S.E 0.37, min–max 1–12
weeks), which supports previous findings that flares last
‘a few days to a few weeks’ [3]. There was an incidence of
1.8% (95% CI 1.5, 2.1%) new major/generalized flares per
week.
Discussion
This is the first study to quantify the average level of
change in disease activity and function during a disease
flare in patients with AS. Consistent with the subjective
concept of flare of disease activity, there is a clinically
relevant change in disease activity score (BASDAI)
during a minor/localized flare, but not in function.
However, during a major/generalized flare the changes
in measures of activity and function reached a clinically
relevant level. Flares of iritis are associated with flares of
the joint disease, which supports previous findings [9].
The study indicates that disease flares are an important
factor in AS, with 70% of the participants reporting a
disease flare in any given week. However, a period of
major/generalized flare is less common, with 12% of
people reporting a major flare in any given week. This
finding is supported by previous research which showed
that most patients have never experienced a major/
generalized flare [3].
The results suggest that there are differences between
the people who experience major flares compared with
those who do not. Patients who reported major flares
had significantly higher levels of disease activity during
flare-free periods than those who did not report any
major flares during the study period. The average dura-
tion of major/generalized flares was 2.4 weeks. Taken
together, these results suggest that assessments of
disease activity prior to anti-TNF therapy could be per-
formed closer together (for example, 4 weeks apart)
than is currently required by NICE guidelines, thereby
minimizing the delay in starting treatment and discomfort
experienced by the patient. Further studies are required to
confirm these findings as they have direct implications
for treatment.
Furthermore, it is possible that those who experience
major flares already have more severe underlying disease
or are at risk of developing more severe disease in the
future. Our study format did not allow us to comment on
the pattern of these participants’ disease flares or activity
in the years preceding the study period. Further research
could look at the radiographs and MRI scans of those
reporting major flares to investigate if this could be used
as a marker to predict future severe disease changes, and
thereby help identify people for early aggressive therapy
with agents such as the anti-TNF therapies.
This study gives the first estimates of the number of
people with AS experiencing minor and major disease
flares over a 3-month period. However, there are limita-
tions to this study, such as an objective accepted defini-
tion of flare does not yet exist. In addition, the database
was based on a cohort of self-selected people with AS
who were willing to take part in an online self-help trial.
As a result, the subgroup of patients recruited would have
been self motivated and maybe more likely to feel that
TABLE 2 The flare-free period for people who reported major/generalized flares (second column) and did not report
major/generalized flares (third column)
No flare period
(reported major/
generalized
flares) (n=27)
No flare period
(did not report
major/generalized
flares) (n=56)
Difference
(95% CI)
BASDAI, mean (S.D.) 2.5 (1.6) 1.5 (1.6) 1.0 (0.2, 1.6)
BASFI, mean (S.D.) 3.5 (3.0) 1.8 (2.3) 1.7 (0.4, 2.8)
Night pain, mean (S.D.) 2.4 (2.1) 1.1 (1.6) 1.3 (0.3, 2.0)
Iritis 0 0
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recruited through secondary-care clinics, they may have
less severe disease than patients recruited in traditional
hospital-based studies. However, even among less severe
patients there are high rates of disease flare and active
disease. For comparison, the average BASDAI in the first
week of this study was 3.7 (S.D 2.1), which is similar to
baseline levels recorded in studies such as the German
Spondyloarthritis Inception that reported baseline
BASDAIs of 3.9 (S.D. 2.1). The use of self-completed
online questionnaires may lead to an under reporting of
the most severe disease flares, as the person may be
unable to use the computer during these periods. For
example, 27% of missing weeks are preceded by a
period of major flare. It is possible that participants who
failed to provide data during the study may have done so
due to the actual flare of their disease. In addition, it
cannot be ruled out that other conditions such as depres-
sion, FM and OA may have affected participants’
self-reported measures.
In summary, the findings from this study show that
the majority of patients even with ‘mild AS’ have active
disease and experience a high level of localized disease
flares. As expected, the subjective reporting of ‘flares’ cor-
related with a validated measure of disease activity
(BASDAI), which increased by 50–90% in minor/localized
flare and by 90–250% in major/generalized flare. This study
is exploratory in nature and can be seen largely as
hypothesis-generating research. The results suggest that
most major/generalized flares are short lived and that
people who experience major/generalized flares appear to
have higher levels of flare-free disease activity. This has
implications for the assessments before starting anti-TNF
therapy and may suggest that the presence of reported
major/generalized flares could be used to help in early iden-
tification of those patients who may require and benefit
from early aggressive intervention. There may also be an
incremental pattern of disease activity in some patients and
the pattern of disease flares in AS is worthy of further study.
Rheumatology key messages
. The majority of AS patients report disease flares.
. Patients reporting generalized flares appear to
develop more severe disease than those reporting
localized flares.
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